{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:00Z","timestamp":1792173300709,"version":"4.4.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Background<\/jats:title>\n Next-generation sequencing (NGS) turnaround times (TAT) exceed two weeks and can delay the initiation of targeted therapy. Rapid cartridge-based platforms such as Idylla deliver single-gene or fusion results from minimal cytology material within hours, but time savings have not been systematically quantified.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Forty-two cases of non-small cell lung carcinoma, thyroid carcinoma, melanoma, and mammary analogue secretory carcinoma of the salivary gland that underwent both Idylla testing (\n KRAS<\/jats:italic>\n ,\n EGFR<\/jats:italic>\n ,\n BRAF,<\/jats:italic>\n and GeneFusion assays) and orthogonal NGS at a single academic center were reviewed. NGS TAT was calculated from specimen collection to report release, and Idylla results were modeled as available one day after collection. The primary outcome was per-case time savings (NGS TAT minus one day); treatment timelines were reconstructed from the medical record. Analyses were descriptive; no inferential testing was performed. A sensitivity analysis varied the modeled Idylla TAT from 1 to 3 days, and an adjusted estimate assigned no time saving to the two cartridge results that were not actionable on the day of collection.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The median NGS TAT across all 42 cases was 20.0 days (IQR, 17.0\u201323.8; range, 8\u201351). Against the modeled 1-day Idylla TAT, the median time savings was 19.0 days per case (IQR, 16.0\u201322.8; range, 7\u201350), totaling 858 patient-days. Assigning no time saving to those two cases gave a median of 18.0 days and 817 patient-days. No patient received therapy that was subsequently contradicted by the sequencing result. In thirteen patients, the sequencing interval alone exceeded three weeks, and in seven, no systemic therapy was underway while the result was awaited.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Same-day cartridge-based testing from cytology and small biopsy specimens could provide actionable results a median of 19 days earlier than standard NGS. Whether this translates into earlier treatment initiation was not assessed and requires prospective evaluation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0360239","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:33:11Z","timestamp":1792171991000},"page":"e0360239","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying the diagnostic time gap in precision oncology: A retrospective analysis of potential time savings from same-day cartridge-based molecular testing versus next-generation sequencing in cytology specimens"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4931-1140","authenticated-orcid":true,"given":"Kevin","family":"Tran","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, Texas, United States of America"],"department":["Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Chen","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, Texas, United States of America"],"department":["Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-184X","authenticated-orcid":true,"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, Texas, United States of America"],"department":["Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine"]},{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, Texas, United States of America"],"department":["Sections of Cytopathology and Breast Pathology, Department of Anatomic Pathology, Division of Pathology and Laboratory Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-458X","authenticated-orcid":true,"given":"Gloria Hopkins","family":"Sura","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, Texas, United States of America"],"department":["Sections of Cytopathology and the Molecular Diagnostic Laboratory, Department of Anatomic Pathology, Division of Pathology and Laboratory Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"21","key":"pone.0360239.ref001","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.3390\/cancers16213654","article-title":"The impact of next-generation sequencing workflows on outcomes in advanced lung cancer: A retrospective analysis at one academic health system","volume":"16","author":"CV Vakkalagadda","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0360239.ref002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer","volume":"9","author":"P-J Volders","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"pone.0360239.ref003","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.22930","article-title":"Same-day molecular testing for targetable mutations in solid tumor cytopathology-The next frontier of the rapid on-site evaluation","volume":"133","author":"JB Iorgulescu","year":"2025","journal-title":"Cancer Cytopathol"},{"issue":"5","key":"pone.0360239.ref004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"AJ Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0360239.ref005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/cancers15010292","article-title":"Robust performance of the novel research-use-only Idylla GeneFusion assay using a diverse set of pathological samples with a proposed 1-day workflow for advanced NSCLC evaluation","volume":"15","author":"A Leone","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0360239.ref006","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/dc.24378","article-title":"Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis","volume":"48","author":"C De Luca","year":"2020","journal-title":"Diagn Cytopathol"},{"issue":"5","key":"pone.0360239.ref007","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/cyt.13406","article-title":"Rapid molecular profiling utilising minimal quantities of endobronchial ultrasound-guided aspirates for the detection of Epidermal Growth Factor Receptor, KRAS, ALK, ROS1, RET, NTRK and MET gene alterations from patients with non-small-cell lung carcinomas on the Biocartis Idylla\u2122 platform","volume":"35","author":"A Haragan","year":"2024","journal-title":"Cytopathology"},{"key":"pone.0360239.ref008","doi-asserted-by":"crossref","first-page":"108623","DOI":"10.1016\/j.lungcan.2025.108623","article-title":"Diagnostic accuracy of the Idylla\u2122 mutation test for detecting EGFR mutations in non-small cell lung cancer: A meta-analysis","volume":"205","author":"M P\u00e9rez-P\u00e9rez","year":"2025","journal-title":"Lung Cancer"},{"issue":"3","key":"pone.0360239.ref009","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/diagnostics15030321","article-title":"High incidence of false positives in EGFR S768I mutation detection using the Idylla qPCR system in non-small cell lung cancer patients","volume":"15","author":"M Carnero-Gregorio","year":"2025","journal-title":"Diagnostics"},{"issue":"1","key":"pone.0360239.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2025.08.018","article-title":"Adverse effects of health plan prior authorization on clinical effectiveness and patient outcomes: A systematic review","volume":"139","author":"J Murphy","year":"2026","journal-title":"Am J Med"},{"issue":"8","key":"pone.0360239.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221123","article-title":"Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay","volume":"14","author":"A Vall\u00e9e","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"pone.0360239.ref012","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/dc.24897","article-title":"Feasibility and performance of the Idylla\u2122 NRAS\/BRAF cartridge mutation assay on thyroid liquid-based fine-needle aspiration","volume":"49","author":"M Hamadou","year":"2021","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"pone.0360239.ref013","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jclinpath-2016-204025","article-title":"The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: Comparison with PNA-clamping PCR, real-time PCR and pyrosequencing","volume":"70","author":"M-K Yeo","year":"2017","journal-title":"J Clin Pathol"},{"issue":"1","key":"pone.0360239.ref014","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.22925","article-title":"A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens","volume":"133","author":"MH Maher","year":"2025","journal-title":"Cancer Cytopathol"},{"issue":"10","key":"pone.0360239.ref015","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.3390\/curroncol29100624","article-title":"Improving time-to-treatment for advanced non-small cell lung cancer patients through faster single gene EGFR testing using the Idylla\u2122 EGFR testing platform","volume":"29","author":"N Banyi","year":"2022","journal-title":"Curr Oncol"},{"issue":"12","key":"pone.0360239.ref016","doi-asserted-by":"crossref","first-page":"104245","DOI":"10.1016\/j.labinv.2025.104245","article-title":"Ultrarapid EGFR testing in non-small cell lung carcinoma patients: Findings from a canadian clinical testing workflow","volume":"105","author":"K Fitzsimmons","year":"2025","journal-title":"Lab Invest"},{"issue":"6","key":"pone.0360239.ref017","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.3390\/curroncol28060376","article-title":"Contribution of the IdyllaTM system to improving the therapeutic care of patients with NSCLC through early screening of EGFR mutations","volume":"28","author":"C Petiteau","year":"2021","journal-title":"Curr Oncol"},{"key":"pone.0360239.ref018","doi-asserted-by":"crossref","first-page":"1610707","DOI":"10.3389\/pore.2023.1610707","article-title":"FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC","volume":"29","author":"A Behnke","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"pone.0360239.ref019","article-title":"Clinical utility of rapid EGFR genotyping in advanced lung cancer","volume":"2018","author":"I Dagogo-Jack","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"pone.0360239.ref020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/jalm\/jfad104","article-title":"Benefits of implementing reflex genomic analysis for nonsmall cell lung cancer","volume":"9","author":"BF Smith","year":"2024","journal-title":"J Appl Lab Med"},{"issue":"4","key":"pone.0360239.ref021","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.esmoop.2023.101587","article-title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: Expert consensus on the rationale and considerations for implementation","volume":"8","author":"JR Gosney","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"pone.0360239.ref022","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/curroncol28020102","article-title":"Improvement of EGFR testing over the last decade and impact of delaying TKI initiation","volume":"28","author":"F Blanc-Durand","year":"2021","journal-title":"Curr Oncol"},{"issue":"4","key":"pone.0360239.ref023","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"GJ Riely","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"pone.0360239.ref024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"13","author":"NI Lindeman","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"pone.0360239.ref025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36469\/jheor.2023.77686","article-title":"Fast in-house next-generation sequencing in the diagnosis of metastatic non-small cell lung cancer: A hospital budget impact analysis","volume":"10","author":"U Silas","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"issue":"10","key":"pone.0360239.ref026","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/13696998.2020.1789152","article-title":"Costs of in-house genomic profiling and implications for economic evaluation: A case example of non-small cell lung cancer (NSCLC)","volume":"23","author":"KM Johnston","year":"2020","journal-title":"J Med Econ"},{"issue":"2","key":"pone.0360239.ref027","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3390\/curroncol30020180","article-title":"Cost savings of expedited care with upfront next-generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current Canadian practices","volume":"30","author":"BS Sheffield","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"pone.0360239.ref028","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/13696998.2024.2314430","article-title":"Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer","volume":"27","author":"CM Bestvina","year":"2024","journal-title":"J Med Econ"},{"key":"pone.0360239.ref029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model","volume":"3","author":"NA Pennell","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"pone.0360239.ref030","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","article-title":"Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: A literature review","volume":"27","author":"M Mirza","year":"2024","journal-title":"Value Health"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0360239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:33:16Z","timestamp":1792171996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0360239"}},"subtitle":[],"editor":[{"given":"Kazunori","family":"Nagasaka","sequence":"first","affiliation":[{"name":"Teikyo University: Teikyo Daigaku","place":["JAPAN"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0360239","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]}}}